Zogenix Announces New Efficacy Data from Long-Term Study of Low-Dose Fenfluramine for Treatment of Dravet Syndrome
May 27, 2015 at 08:32 AM EDT
Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing and commercializing unique therapies for the treatment of central ...
